OTCMKTS:SPRCY SciSparc (SPRCY) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free SPRCY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.99▼$4.9050-Day Range$4.00▼$4.0052-Week Range$2.75▼$12.25Volume12,500 shsAverage Volume10,035 shsMarket Capitalization$4.15 millionP/E Ratio0.27Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get SciSparc alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About SciSparcSciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. SPRCY Stock News HeadlinesApril 11, 2024 | benzinga.comLatest News for SciSparc Stock (NASDAQ:SPRC)September 10, 2023 | washingtonpost.comSnack company removes spicy ‘One Chip Challenge’ product after teen’s deathApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.May 20, 2023 | wsj.comGrilled Oysters With Spicy Garlic Butter and Parmesan Bread CrumbsMay 6, 2023 | ca.finance.yahoo.comClearmind Medicine Inc. (CMND)February 19, 2023 | marketwatch.comSciSparc Shares Rise 22% on Joint Venture MilestoneFebruary 19, 2023 | benzinga.comWhy SciSparc Shares Are Moving During Friday's SessionSeptember 7, 2021 | finance.yahoo.comSciSparc Awarded Three Patents For Its Novel Compounds and MethodsApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… August 29, 2021 | finanznachrichten.deSciSparc Ltd.: SciSparc Announces Completion of Corporate Rebranding and Launch of New WebsiteAugust 19, 2021 | barrons.comSciSparc Ltd. ADRAugust 4, 2021 | finance.yahoo.comSciSparc Announces Completion of Corporate Rebranding and Launch of New WebsiteAugust 2, 2021 | finance.yahoo.comSciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical StudyJuly 29, 2021 | msn.comIronwood (IRWD) Hits 52-Week High, Can the Run Continue?July 27, 2021 | yahoo.comSeller beware? Stars aren't fetching much at the MLB trade deadlineJuly 26, 2021 | finance.yahoo.comSciSparc Announces Updates Regarding its Phase IIb Study in Tourette SyndromeSee More Headlines Receive SPRCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SciSparc and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:SPRCY CUSIPN/A CIK1611746 Webtherapixbio.com Phone972-3610-3100FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.27 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.05 Quick Ratio2.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$2.65 per share Price / Cash Flow1.51 Book Value$1.38 per share Price / Book2.90Miscellaneous Outstanding Shares1,037,000Free FloatN/AMarket Cap$4.15 million OptionableNot Optionable Beta-0.08 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Oz Adler CPA (Age 34)Chief Financial Officer Comp: $231kDr. Adi Zuloff-Shani (Age 52)Chief Technologies Officer Comp: $159kMr. Amitai Weiss (Age 59)CEO & Director Key CompetitorsEnsysce BiosciencesNASDAQ:ENSCBiophytisNASDAQ:BPTSGenprexNASDAQ:GNPXArtelo BiosciencesNASDAQ:ARTLVirpax PharmaceuticalsNASDAQ:VRPXView All Competitors This page (OTCMKTS:SPRCY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.